Karelia Ruiz
Internal Medicine · Hialeah, FLNPI 1508864356
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 635 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,475 and has fallen 71.8% since, to $698 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- Amgen$1K
- Lilly USA, LLC$976
- AstraZeneca$844
- Boehringer Ingelheim$562
- plus $6K from 33 others
Across 96 payments — averaging $81,138 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$6.7M
- Applied Therapeutics, Inc.$672K
- Astrazeneca UK Limited$212K
- First Wave Biopharma, Inc.$108K
- Novartis$104K
- Teva Pharmaceuticals USA, Inc.$9K
What the payments were for
- Food & beverage$12,19599%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 72 | $1,388 |
| GSK | 66 | $1,359 |
| Amgen | 43 | $1,044 |
| Lilly USA, LLC | 65 | $976 |
| AstraZeneca | 46 | $844 |
| Boehringer Ingelheim | 29 | $562 |
| Sanofi-aventis U.S. LLC | 32 | $560 |
| AbbVie(2 entities) | 33 | $524 |
| Sumitomo Pharma America, Inc. | 21 | $483 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $478 |
| Astellas Pharma US Inc | 21 | $464 |
| Kowa Pharmaceuticals America, Inc. | 28 | $444 |
| Amneal Pharmaceuticals LLC | 22 | $386 |
| Johnson & Johnson | 20 | $360 |
| Merck | 17 | $349 |
| Novartis | 16 | $281 |
| Exact Sciences | 12 | $251 |
| Amarin Pharma, Inc. | 10 | $183 |
| Astrazeneca UK Limited | 1 | $165 |
| Heartflow, Inc. | 2 | $163 |
| Bayer | 7 | $157 |
| Pfizer | 7 | $142 |
| Xeris Pharmaceuticals, Inc. | 6 | $111 |
| Sunovion Pharmaceuticals Inc. | 5 | $105 |
| Radius Health, Inc. | 5 | $98 |
| Inspire Medical Systems, Inc. | 2 | $73 |
| Esperion Therapeutics, Inc. | 3 | $66 |
| Dexcom, Inc. | 2 | $34 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Medicure Pharma Inc. | 1 | $31 |
| Nabriva Therapeutics, PLC | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Abbott | 1 | $18 |
| Dermira, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$275
- FFRct$147
- TRELEGY ELLIPTA$125
- Repatha$117
- Ozempic$109
How this compares
$12,299 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $141,611 |
| MounjaroTirzepatide | 81 | $116,121 |
| TradjentaLinagliptin | 87 | $103,562 |
| JardianceEmpagliflozin | 73 | $90,945 |
| ProliaDenosumab | 46 | $81,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $75,040 |
| EliquisApixaban | 49 | $74,691 |
| JanuviaSitagliptin Phosphate | 55 | $70,817 |
| LinzessLinaclotide | 54 | $69,019 |
| CreonLipase/Protease/Amylase | 18 | $54,451 |
| FarxigaDapagliflozin Propanediol | 40 | $46,597 |
| VascepaIcosapent Ethyl | 54 | $45,351 |
| XareltoRivaroxaban | 28 | $41,228 |
| EntrestoSacubitril/Valsartan | 24 | $32,651 |
| GemtesaVibegron | 36 | $31,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $562 | $194,508160 claims |
| AbbVieLinzess, Creon, Synthroid | $524 | $145,150248 claims |
| Novo NordiskOzempic | $1,388 | $141,61183 claims |
| Lilly USA, LLCMounjaro, Trulicity | $976 | $132,61596 claims |
| MerckJanuvia, Janumet | $349 | $95,89173 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $844 | $87,11585 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,359 | $86,03279 claims |
| AmgenProlia | $1,044 | $81,24746 claims |
| PfizerEliquis | $142 | $74,69149 claims |
| Johnson & JohnsonXarelto | $360 | $41,22828 claims |
| NovartisEntresto | $281 | $32,65124 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $483 | $31,01836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Hialeah
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.